Editas’s EDIT-101 Faces Uncertainty As LCA10 Data Lack BRILLIANCE

Editas announced data from the Phase I/II BRILLIANCE trial of EDIT-101 in LCA10 • Source: Shutterstock

More from Gene Therapies

More from Advanced Therapies